*These authors contributed equally to this work.
Introduction
The development of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in 1987 has provided a highly successful antiretroviral therapy (ART) and made HIV infection a manageable clinical entity (Massimo Andreoni et al., 2015; Bhatti et al., 2016; Ray et al., 2016) . The clinical challenges now confronting HIV-positive patients have shifted significantly from AIDS to chronic non-communicable diseases, among which cardiovascular disease (CVD) is a major issue (Triant et al., 2007; Lang et al., 2010; Baker and Lundgren, 2011; Boccara et al., 2013; Freiberg et al., 2013; Hemkens and Bucher, 2014; Althoff et al., 2015) . Recently, the National Heart, Lung, and Blood Institute (NHLBI) of the NIH recognized the high rates of CVD in HIV patients (Shah et al., 2015) . In addition to immunological defects and metabolic disorders, the adverse effects of antiretroviral therapy have become a particular concern within factors that may potentially contribute to HIV-related CVD (de Gaetano et al., 2004) . Importantly, both arterial and small-vessel vasculopathy are indicated, in which endothelial dysfunction could be a major cause.
So far, a number of laboratory studies have revealed that NRTIs have a detrimental effect in the development of atherosclerosis, a major aortic disease. The long-term administration of NRTIs significantly exacerbated the intima-media remodelling of the aorta and carotid artery in mice, and this was associated with endothelial dysfunction (Roy et al., 2002; Jiang et al., 2009; . Furthermore, mechanical investigations have shown that NRTIs cause mitochondrial dysfunction and oxidative stress in arterial endothelial cells (ECs) (Jiang et al., 2007) . However, a number of studies have reported that antiviral treatment in HIV-positive patients inhibited the occurrence and progression of Kaposi sarcoma, an AIDS-defining illness characterized by an abundant growth of immature microvessels originating from the lymphatic endothelium (Beckstead et al., 1985) and mesenchymal-endothelial transitions (Gurzu et al., 2013) . These clinical cases suggest NRTIs can have potent effects on angiogenesis and lymphangiogenesis. Moreover, NHLBI of the NIH demonstrated a close correlation between antiviral treatment and endothelial dysfunction in HIV-positive patients. Because angiogenic capability is one of the basic functions of endothelial cells, this characteristic is an indicator of the interference of NRTIs in angiogenesis. Therefore, the ARTs used to treat HIV could be potent anti-angiogenic molecules. However, the biological effect of ART on the growth of vasculature remains elusive.
The human vascular system comprises blood vessels and lymphatic vessels, which form diffused networks among most cells of the body for material exchange, signal communication and homeostasis maintenance in the healthy organism (McColl et al., 2004; Adams and Alitalo, 2007; Wang and Oliver, 2010b; Choi et al., 2012) . The new vessel growth from pre-existing vessels of these two vascular systems plays a central role in tissue morphogenesis during development and adult repair, coordinating the proliferation, migration and adhesion of ECs under the control of angiogenic signalling (Eichmann and Simons, 2012; Marcelo et al., 2013) . VEGFs, FGFs and their receptors are key regulators in angiogenesis and lymphangiogenesis via typical receptor tyrosine kinase (RTK) pathways; VEGF-A/VEGFR2 and bFGF/ FGFR1 are critical mediators in angiogenesis, while VEGF-C/VEGFR3 is a key regulator of lymphatic angiogenesis (Horowitz and Simons, 2008; Wang et al., 2010a; Murakami et al., 2011) . Upon binding of these growth factor ligands, corresponding RTKs undergo dimerization, followed by intrinsic phosphorylation/activation and consequent internalization and endocytosis of receptor-ligand complexes for triggering signalling transduction (Lanahan et al., 2010; Zhang et al., 2013) .
Unlike other cells, which contain large quantities of mitochondria that can satisfy the requirements for high energy, ECs obtain most of their energy through glycolytic metabolism rather than through mitochondria-dependent oxidative phosphorylation (Freed and Gutterman, 2013; Tang et al., 2014) . Although ECs only have relatively low levels of mitochondria, these endothelial mitochondria provide prominent signals for cellular responses (Tang et al., 2014) . To this end, mitochondria-derived ROS (mROS) is the major signal effector in ECs, and is regulated through the mitochondrial redox system, including the free radical scavengers recombinant human superoxide dismutase (MnSOD) and thioredoxin protein 2 (TRX2) (Bir et al., 2012; Zhou et al., 2013; Kim and Byzova, 2014) . Under stress conditions, excessive amount of mROS are produced, which overturn the buffering capacity of the redox system, and thereby regulates the physiological functions of an organelle or causes cellular dysfunction (Bir et al., 2012) . Specifically, excessive mitochondrial ROS has been associated with a disruptive effect on RTK endocytosis, which is the upstream event required for RTK activation (Ushio-Fukai and Nakamura, 2008) . Without endocytosis, the VEGF and FGF receptors cannot be further phosphorylated, and the signalling transductions are consequently suppressed.
In the present study, we investigated the effect of representative nucleoside/nucleotide analogues of NRTIs [tenofovir disoproxil fumarate (TDF), azidothymidine (AZT) and lamivudine (3TC)], an integral component of ART, on microvascular angiogenesis. We demonstrated that pharmaceutical doses of NRTIs profoundly inhibit vascular angiogenesis and lymphangiogenesis both in vivo and in vitro. In addition, NRTI treatment induced mitochondrial oxidative stress and the subsequent impairment of RTK signalling in ECs. Specifically, NRTIs significantly restrained the endocytosis of RTKs into early endosomes and slightly affected their internalization.
Methods

Mice and diets
Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . All animal studies were approved by the Institutional Animal Care and Use Committee of Zhejiang University and adhered to the Guide for the Care and Use of Laboratory Animals. Eight-week-old male C57BL/6 mice (18-20 g) were purchased from Slac Laboratory Animal (Shanghai, China). The mice were acclimatized to the room for 1 week after arrival and maintained on a normal 12 h light-dark cycle. The mice were housed in conventional cages (six animals per cage) with free access to standard pellet diet and water. They were kept in specific pathogen-free conditions: temperature 24 ± 2°C, relative humidity 60-70%. Standard wood chips for mice were used as bedding material. The mice were randomly separated into two groups, which were administered distilled H 2 O (control) or TDF (50 mg·kg À1 ) by oral gavage for five consecutive days to ensure that serum concentrations were maintained above those needed to achieve therapeutic effects in humans (Jiang et al., 2009; Jiang et al., 2010) . For each group, a cage was randomly selected from the pool of cages. The experimenters were blinded to the animal treatment, histological analyses and the data analyses. For the angiogenesis/lymphangiogenesis assays, the mice were anaesthetized with ketamine (200 mg·kg À1 ) and xylazine (10 mg·kg À1 ) through an i.p. injection. Anaesthesia was monitored using toe pinching. After the experiments, the mice were killed by cervical dislocation.
Mouse ear angiogenesis/lymphangiogenesis assay
Adenoviruses encoding VEGF-A 164 (1 × 10 9 pfu), bFGF
(1 × 10 9 pfu), VEGF-C (1 × 10 9 pfu) or β-gal control (1 × 10 9 pfu) were injected, i.d., into mouse ear skin. Ten days later, the mice were killed, and the ears were photographed using a stereomicroscope. The mouse ears were subsequently fixed overnight in 4% paraformaldehyde at 4°C. The ears were washed three times with 1× PBS for 1 h and stained with anti-mouse CD31 (rat polyclonal, 10 μg·mL À1 ; BD Pharmingen, San Diego, CA, USA) or LYVE-1 antibody (goat polyclonal, 10 μg·mL À1 ; R&D, Minneapolis, MN, USA) diluted at 4°C for 24 h. The ears were subsequently washed threetimeswith1× PBS for 1 h followed by Alexa Fluor 488-or 594-conjugated secondary antibody (donkey polyclonal, 5-μg·mL
À1
; Molecular Probes) at 4°C for another 24 h. The coverslips were mounted onto slides using Vectashield mounting medium (Vector Laboratories, CA, USA). Images were obtained using a Nikon fluorescence microscope (Tokyo, Japan) and analysed using Nikon NIS-Elements software. Quantitative analyses were conducted blindly.
In vivo Matrigel plug assay
Growth factor-reduced Matrigel (BD Biosciences) was premixed with murine VEGF-A 164 (50 ng·mL À1 ), murine bFGF (100 ng·mL À1 ) or murine VEGF-C (100 ng·mL À1 ) and heparin (20 U·mL À1 ). Recombinant murine VEGF and murine bFGF were purchased from Peprotech (Rocky Hill, NJ, USA). Murine VEGF-C was obtained from Sigma-Aldrich (St. Louis, MO, USA), and 100 μL of the samples was injected s.c. into 8-week-old mice. Two weeks later, the mice were killed, and the plugs were removed and imaged. Subsequently, 5 μm serial sections were cut from frozen, optimal cutting temperature compound-embedded plugs and mounted onto pre-cleaned glass slides. Prior to staining, the slides were placed at room temperature for half an hour and fixed in À20°C acetone for 10 min, rinsed three times in PBS for 15 min and subsequently blocked in 10% normal horse serum for 1 h at room temperature. The slides were incubated overnight using anti-mouse CD31 antibody (rat polyclonal, 10 μg·mL
À1
; BD Pharmingen) or LYVE-1 antibody (goat polyclonal, 10 μg·mL À1 ; R&D) at 4°C for 24 h. The sections were subsequently washed with 1× PBS for half an hour, followed by Alexa Fluor 488-or 594-conjugated secondary antibody (donkey polyclonal, 5 μg·mL
, Molecular Probes, Eugene, OR, USA) at 4°C for 24 h. The coverslips were mounted onto slides using Vectashield mounting medium, and images were captured using a Nikon fluorescence microscope (Tokyo, Japan). The images were analysed using Nikon NIS-Elements software. Quantitative analyses were conducted blindly.
Cell culture
HUVECs and human dermal microvascular endothelial cells (HMVECs) were purchased from Lonza (Allendale, NJ, USA) and cultured with endothelial cell growth medium (EGM)-2 and EGM-2 MV (Lonza) respectively. Human dermal lymphatic endothelial cells (HDLECs) were purchased from PromoCell (Heidelberg, German) and cultured with endothelial cell growth medium MV-2 (PromoCell). Only cells from passages 3-8 were used for experiments. The 10 μM doses of drugs were carefully selected according to the International US AIDS Panel, and the average plasma drug concentrations were as previously reported (Chittick et al., 2006; Jiang et al., 2007; Xue et al., 2013) . For all in vitro experiments, the cells were treated with drugs for 48 h prior to testing. All cell lines were cultured at 37°C in 5% CO 2 . For treatment with different growth factors, the cells were serum starved overnight and treated with VEGF-A 165 (50 ng·mL À1 ), bFGF (100 ng·mL À1 ), or VEGF-C (100 ng·mL À1 ) for various times. Recombinant human VEGF-A 165 , human bFGF and human VEGF-C were from Peprotech. Manganese (III) tetrakis (N-methyl-2-pyridyl) porphyrin (MnTMPyP) pentachloride was purchased from ApexBio (Houston, TX, USA).
In vitro EC migration and tube formation assays
Monolayer EC migration. For monolayer migration, ECs were seeded onto 12-well tissue culture plates and grown to confluence. The next day, control or NRTI-treated ECs were subjected to a 'wound healing' assay with a 200 μL plastic pipette tip. EC migration in the culture was determined by measuring wound areas in cell monolayers. Cells were dyed, after 48 h, using 0.2% crystal violet (Sigma-Aldrich) dissolved in PBS containing 10% ethanol. Images were captured using a Nikon microscope, and wound healing (% closure) was subsequently measured and analysed.
EC transwell migration assay. Cell migration was examined using a transwell fitted with an 8 μm pore size polycarbonate filters (Corning, NY, USA). Briefly, the lower chambers were filled with EGM-2 (Lonza), and 1 × 10 5 control or NRTI-treated ECs suspended in EBM-2 were added into each upper chamber. The cells were subsequently cultured for 8 h at 37°C in the presence of 5% CO 2 in a humidified incubator. Cells that did not migrate through the filters were removed with cotton swabs, and cells that migrated to the lower surfaces of the filters were stained for 15 min with 0.2% crystal violet in 10% ethanol. The chambers were washed thoroughly in a water reservoir, and the interior was dried with cotton swabs. Cells on the lower surfaces of the filters were counted under a microscope.
EC tube formation assay. Control or NRTI-treated ECs were plated onto solidified Matrigel (Corning)-coated 48-well plates at 1 × 10 4 cells per well in EGM-2 for 6 h at 37°C in the presence of 5% CO 2 in a humidified incubator. Images of the formation of tube or vascular-like structures were observed using a Nikon inverted phase contrast microscope, and tube formation was quantified by measuring the number of branches produced.
Apoptosis assay
Alexa Fluor 488 annexin V/Dead Cell Apoptosis Kit (SigmaAldrich) was used to measure cell apoptosis. Control or NRTI-treated ECs were incubated with reagents from the kit according to the manufacturer's instructions, followed by flow cytometry analysis. The rate of apoptosis was expressed as a percentage of apoptotic cells relative to the total number of cells per condition. Cells treated with staurosporine (1 mM final concentration) for 3 h were used as the positive control.
Cell lysis and Western blot analysis
To obtain cell lysates, the cells were washed with cold PBS and lysed for 10 min on ice in a RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitor mixture (Roche, Basel, Switzerland) and phosphatase inhibitor mixture (Roche). The cell lysates were subsequently centrifuged at 14 000× g at 4°C for 15 min, and the supernatants were immediately used for immunoblotting analyses. The complexes were loaded in 8-10% polyacrylamide gels and transferred onto PVDF membranes. The membranes were then blocked with 5% skimmed milk diluted in PBS containing 0.05% 
Matrigel lysis and Western blot analysis
Matrigel samples were obtained from mice in vivo and cut into pieces. The gel pieces were lysed using RIPA lysis buffer for 10 min on ice, followed by shearing with super sonication. Matrigel lysates were subsequently centrifuged at 14 000× g at 4°C for 15 min. The supernatants were used for Western blot analyses.
Analysis of VEGFR2, FGFR1, VEGFR-3 internalization and surface expression using flow cytometry
Control or NRTI-treated ECs were serum-starved overnight, subsequently placed on ice and incubated with specified antibody for 30 min. PE anti-human CD309 (VEGFR2) and PE anti-human VEGFR-3 (FLT-4) were purchased from BioLegend (mouse polyclonal, 2.5 μg·mL À1 ; San Diego, CA, USA), and FGFR1 antibody (N-term) was purchased from ABGENT (rabbit polyclonal, 2.5 μg·mL À1 ; San Diego, CA, USA). Control or NRTI-treated ECs were subsequently stimulated with VEGF-A 165 (50 ng·mL À1 ), bFGF (100 ng·mL À1 ) or VEGF-C (100 ng·mL À1 ) for pre-determined time intervals at 37°C and subsequently rinsed with ice-cold PBS or acidic wash (PBS, pH 2.5), respectively, to remove the remaining cell surface labelled receptors. The cells were subsequently treated with Accutase-Enzyme Cell Detachment Medium (eBioscience, San Diego, CA, USA), centrifuged and resuspended in PBS/1%BSA/1%formaldehyde, followed by flow cytometry analysis using a FACS-Calibur instrument (Becton Dickinson, Franklin Lakes, NJ, USA).
Colocalization of VEGFR2, FGFR1, VEGFR-3 and EEA1
Control or NRTI-treated ECs were grown on gelatin-coated glass coverslips (Thermo Fisher, USA) and starved overnight with 0.5% FBS. overnight, followed by secondary antibody. The samples were observed through a laser-scanning confocal microscopy with an X63 objective.
Quantification of mtDNA copy number RT-qPCR was performed with the All-in-one qPCR Mix (GeneCopoeia, Amaranth Drive Germantown, MD, USA) in triplicate on a 96-well plate with a CFX96 Connect RealTime PCR Detection System (Bio-Rad). GAPDH served as an internal control. Primers with the following sense sequences were used:
Determination of mROS production
MitoSOX (Invitrogen, Carlsbad, CA, USA) was used to determine mitochondria-derived ROS production according to the manufacturer's instructions. The images were observed using a Nikon fluorescence microscope and analysed using Nikon NIS-Elements software.
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Statistical analysis was performed using GraphPad Prism software. ImageJ, Photoshop CS and Illustrator CS software were used for image processing according to the general guidelines. All data, expressed as the means ± SEM, were analysed using Student's two-tailed t-test or one-way ANOVA. P-values < 0.05 were considered statistically significant.
Chemicals and reagents
TDF and 3TC were purchased from Energy Chemical (Shanghai, China). AZT was purchased from Sigma-Aldrich. Small amounts of TDF, AZT and 3TC were also obtained from the NIH AIDS Research and Reference Reagent Programme (Germantown, MD, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c).
Results
NRTIs weaken the angiogenic capability of ECs by disrupting cell proliferation and migration
To determine the effect of NRTIs on angiogenic cell growth, we employed primary cultured HMVECs and HUVECs in an in vitro model of angiogenesis and HDLECs in an in vitro model of lymphangiogenesis. To mimic ART administration, these ECs with pharmaceutical doses of representative NRTIs (TDF, AZT and 3TC). No induction of apoptosis was detected with all the three NRTIs in all the three cell lines ( Figure 1A and Supporting Information Figure S1A ). The growth of ECs was first examined using a monolayer 'wound healing' assay. NRTI treatment resulted in significantly slower wound closure compared to carrier control in all three types of EC growing in full medium (Figure 1 B-E and Supporting Information Figure S1B , C, P < 0.05).
The closure of the wound within 48 h is attributed to two distinct cellular processes, proliferation and migration. Thus, we measured the effect of NRTIs on EC proliferation and migration separately. EC proliferation was measured using a CCK-8 assay and the cell growth curves indicated that NRTI treatment blunted the proliferation of the ECs ( Figure 1F and Supporting Information Figure S1D , P < 0.05). Under the same conditions in full medium, using a transwell migration assay, it was observed that NTRI retarded the migratory capability of the cells ( Figure 1G -J and Supporting Information Figure S1E -F, P < 0.05). Correspondingly, F-actin staining showed that the addition of NRTI destroyed the original organization of microfilaments, which are essential for EC movement (Supporting Information Figure S2 ). To further investigate the effect of NRTIs on the angiogenic ability of ECs, a tube formation assay was performed. Similar to the results obtained with the proliferation and migration analysis, NRTI-treated ECs barely formed hollow lumens and capillary-like structures, while control cells achieved typical capillary-like tube structures ( Figure 1K -N and Supporting Information Figure S1G , H, P < 0.05). Taken together, these findings show that NRTIs specifically disrupt the migration capability of ECs and consequently cellular angiogenesis.
NRTIs block angiogenesis and lymphangiogenesis in vivo
The angiogenic assays in vitro involve multiple proangiogenic factors, which function distinctly in vascular network formation. At the physiological level, the expression of VEGF receptors (VEGFRs) is primarily confined to vascular ECs and lymphatic ECs; FGFR1 is highly expressed in vascular ECs. When new vessels start to grow, the tip cells at the angiogenic fronts migrate towards to the VEGF stimulus that activates the VEGF-VEGFR signalling pathway, leading to the promotion of angiogenesis. Inside the neovascular area, bFGF-activated FGFR signalling is a major force driving the proliferation and maturation of the endothelial network (Horowitz and Simons, 2008; Koch and Claesson-Welsh, 2012; Simons and Eichmann, 2015) . Therefore, as VEGF-A, bFGF and VEGF-C are the most important pro-angiogenic factors, we employed them in endothelial angiogenic assays to investigate the effect of NRTIs on angiogenesis and lymphangiogenesis. To directly assess the effect of NRTIs on vascular responses to these proangiogenic growth factors in vivo, we examined angiogenesis and lymphangiogenesis in the ear and implanted Matrigel plugs in mice using a representative NRTI, TDF.
For the ear angiogenesis model, an adenovirus encoding VEGF-A 164 , bFGF, VEGF-C or β-gal was injected i.d. into mice ears. The angiogenesis/lymphangiogenesis induced by a single growth factor was determined by stereomicroscopy (Figure 2A , D, G). Ear vascular or lymphatic vessels were also visualized using whole-mount immunofluorescent staining with anti-CD31 or anti-LYVE-I antibody ( Figure 2B , E, H with quantifications in Figure 2C , F, I). In these assays, injection of Ad-VEGF-A 164 or Ad-bFGF led to profound local angiogenesis and injection of Ad-VEGF-C resulted in an intense local area of lymphangiogenesis . Branch points were quantified in (L) and (N). Data represent the means ± SEM from triplicates in each group from five independent experiments. Scale bar represents 100 μm. *P < 0.05 versus control; ns, not significant.
in control animals. However, the responses to these three growth factors were significantly reduced in animals after TDF administration (P < 0.05, n = 6). Consistently, the angiogenesis/lymphangiogenesis responses in implanted Matrigel plugs premixed with murine VEGF-A 164 , bFGF or VEGF-C were dramatically decreased in the TDF-treated groups ( Figure 2J , K, M, N, P, Q with quantifications in Figure 2L , O, R, P < 0.05, n = 6), AZT-treated groups (Supporting Information Figure S3A , B, D, E, G, H with quantifications in Supporting Information Figure S3C , F, I, P < 0.05, n = 6) and 3TC-treated groups (Supporting Information Figure S3J , K, M, N, P, Q with quantifications in Supporting Information Figure S3L , O, R, P < 0.05, n = 6).
NRTI treatment suppresses RTK signalling in ECs
In vascular ECs, the corresponding receptors for VEGF-A, bFGF and VEGF-C are from the same group of RTKs, which function as principal regulators of EC growth and angiogenesis (McColl et al., 2004; Wang et al., 2010a) . Thereby, we reasoned that the mechanism by which NTRIs inhibit angiogenesis and lymphangiogenesis involves the interference of RTK signalling in ECs. To this end, primary cultured vascular ECs were treated with VEGF-A, bFGF or VEGF-C, and activation of RTK pathways was determined through Western blotting with phospho-specific antibodies. In HMVECs, VEGF-A induced the phosphorylation of VEGFR2 and its downstream effector Akt, PLCγ and ERK1/2. Consistent with the angiogenesis assays, VEGFR2-mediated activation of PLCγ, ERK1/2 and Akt was substantially weakened in NRTI-treated ECs ( Figure 3A -C, P < 0.05, n = 5). Similar results were obtained using HUVECs (Supporting Information Figure  S4A -C, P < 0.05, n = 5). In addition, in untreated cells bFGF induced the phosphorylation of FGFR1, its adaptor FRS2α, and the downstream Akt and ERK1/2, whereas in the presence of NRTIs these effects of bFGF were blocked in both HMVECs ( Figure 3D -F, P < 0.05, n = 5) and HUVECs NRTIs attenuate angiogenesis and lymphangiogenesis (Supporting Information Figure S4D -F, P < 0.05, n = 5). For lymphangiogenesis, we examined the VEGF-C-activated VEGFR3 pathway in HDLECs and observed that NRTIs consistently suppressed VEGFR3 activation and its downstream effectors ( Figure 3G -I, P < 0.05, n = 5). Notably, we observed that AZT altered the total expression of VEGFR2 and FGFR1 ( Figure 3B , E and Supporting Information Figure S4B , E second rows). The maturation and signal transduction of VEGFR2 and FGFR1 depend on the N-glycosylation of these RTK receptors (Feige and Baird, 1988; Takahashi and Shibuya, 1997; Shen et al., 1998; Duchesne et al., 2006) . Further immunoblot analyses of HMVECs treated with AZT or tunicamycin, an antibiotic that specifically inhibits the N-glycosylation of proteins, were performed. AZT treatment reduced the bands of VEGFR2 and FGFR1 to a single band, whose size coincides with that of the upper band observed in the presence of tunicamycin (Supporting Information Figure S5A , B). Therefore, AZT blocks the maturation of proteins by partially decreasing their glycosylation. However, NRTIs had little effect on endothelial Notch1 signalling, the other classical membrane receptor pathway controlling EC growth. The expression of Notch 1 and its downstream Hes 1 detected in HMVECs and HUVECs was similar with or without NRTI treatment ( Figure 3J ,K and Supporting Information Figure S4G ). Thus, NRTI treatment dampens angiogenic/lymphangiogenic activity by selectively targeting RTK pathways in vascular ECs. The activation of RTKs and their signature downstream molecules were further determined in the Matrigel plugs using Western blotting. Consistent with the results in cultured ECs, TDF significantly blocked RTK signalling in vivo (Supporting Information Figure S4H -J).
Figure 2
Impaired angiogenesis and lymphangiogenesis in TDF-treated mice. (A-I) After receiving distilled water (control) or TDF (50 mg·kg À1 ) for 5 days, C57BL/6 mice were injected with 1 × 109 pfu of adenovirus encoding VEGF-A164, bFGF, VEGF-C or β-gal (Ad-VEGF-A164, Ad-bFGF, Ad-VEGF-C or Ad-LacZ) i.d. into the ears. On day 10, angiogenesis induced by VEGF-A164 and bFGF and lymphangiogenesis induced by VEGF-C were recorded using stereomicroscopy, and representative images of the ears are shown in (A), (D) and (G) respectively. Ear vascular and lymphatic vessels were assessed through whole-mount staining of mouse ears with anti-CD31 and anti-LYVE-I, respectively, using immunofluorescence microscopy. Representative images of the ears with Ad-VEGF-A164, Ad-bFGF and Ad-VEGF-C are shown in (B), (E) and (H) respectively. Positive areas of new microvessels was quantified in (C), (F) and (I). Data represent the means ± SEM; n = 6 mice per group. Scale bar represents 100 μm. *P < 0.05 versus control. (J-R) Matrigel mixed with either PBS (control), VEGF-A164 (50 ng·mL À1 ), bFGF (100 ng·mL À1 ) or VEGF-C (100 ng·mL À1 ) was placed subcutaneously in C57BL/6 mice previously fed with distilled water (control), TDF (50 mg·kg À1 ) for 5 days. On day 10, Matrigel plugs were harvested and recorded using stereomicroscopy. Representative images of plugs are shown in panels (J), (M) and (P). Matrigel plugs were subsequently sectioned, and vascular and lymphatic vessels were subsequently assessed using immunofluorescence staining with anti-CD31 and anti-LYVE-I respectively. Representative images of plugs with Ad-VEGF-A164, Ad-bFGF and Ad-VEGF-C are shown in panels (K), (N) and (Q) respectively. Positive areas of new microvessels were quantified in L, O and R. Data represent the means ± SEM; n = 6 mice per group. Scale bar represents 50 μm. *P < 0.05 versus control.
NRTIs restrain the internalization of RTKs or their endocytosis into early endosomes in ECs
To further investigate the mechanism of the inhibitory effects of NRTIs on endothelial RTK pathways, we examined membrane receptor internalization and endocytosis, two critical steps for the activation of RTK signalling. In HMVECs, flow cytometry analyses demonstrated that VEGF-A-induced VEGFR2 uptake was not affected in the presence of TDF and 3TC ( Figure 4A with quantifications in Figure 4C ). However, AZT treatment promoted VEGFR2 internalization in HMVECs, even without ligand stimulation ( Figure 4B with quantifications in Figure 4C , P < 0.05, n = 5), and a similar pattern also applied for FGFR1 and VEGFR3 (Figure 4D , E, G, H with quantifications in Figure 4F , I). Similar results were also observed in HUVECs (Supporting Information Figure  S6A , B, D, E with quantifications in Supporting Information- Figure S6C , F). Notably, AZT treatment increased both total and internalized RTK levels in the absence of ligand stimulation, which resulted in decreased FGFR1 surface expression; whereas a downward trend was also observed for VEGFR2 and VEGFR3 (Supporting Information Figure S7A -F). Therefore, AZT may block RTK signalling in angiogenesis by disturbing both RTK surface expression and internalization. The effect of TDF and 3TC on RTK intracellular trafficking, transportation of VEGFR2, FGFR1 and VEGFR3 into early endosomes was determined using immunofluorescence microscopy. Upon stimulation by growth factors, RTKs are extensively translocated into EEA1-labelled endosomes in control HMVECs, HUVECs or HDLECs, but the endocytosis of internalized RTK was substantially retarded by either TDF or 3TC ( Figure 4J , L, N and Supporting Information Figure  S6G , I with quantifications in Figure 4K , M, O and Supporting Information Figure S6H , J, P < 0.05, n = 5).
NRTIs affect angiogenesis/lymphangiogenesis by causing mitochondrial oxidative stress
To examine the correlation between cellular stress induced by NRTIs and their inhibitory effects on angiogenesis and lymphangiogenesis, we determined the mitochondrial function, the main end target of antiviral medicine treatment, in NRTI-treated microvascular ECs. Mitochondrial DNA copy number was measured as a parameter of mitochondrial function. After 48 h, NRTIs markedly reduced mitochondrial DNA content ( Figure 5A , B and Supporting Information Figure S8A ), indicating an impairment in mitochondrial gene stability and biogenesis. As expected, excessive mROS production was detected along with this mitochondrial dysfunction in ECs ( Figure 5C , D and Supporting Information Figure S8B , P < 0.05, n = 5). The imbalance of mitochondrial redox was also characterized by changes in the expression of mitochondrial antioxidant catalases. To this end, the expressions of MnSOD, TRX2 and catalase were examined using Western blotting. Upon treatment with NRTIs, the level of MnSOD was elevated and TRX2 was slightly increased, while little change in catalase was detected ( Figure 5E , F and Supporting Information Figure  S8C , P < 0.05, n = 5). Importantly, the exogenous addition of the MnSOD mimic MnTMPyP restored the angiogenic and lymphangiogenic ability of ECs subjected to NRTI-induced impairments. In the presence of MnTMPyP, NRTI-treated ECs demonstrated an improved angiogenic/lymphangiogenic capability, evidenced by enhanced tube formation ( Figure 6A , C with quantifications in Figure 6B , D and Supporting Information Figure S9A with quantifications in Supporting Information Figure S9B , P < 0.05, n = 5). Concomitantly, MnTMPyP reactivated the endothelial VEGFR2, FGFR1 and VEGFR3 signalling, which was retarded by TDF ( Figure 6E -G and Supporting Information Figure S9C , D, P < 0.05, n = 5) and 3TC ( Figure 6H -J, P < 0.05, n = 5). Therefore, ROS derived from dysfunctional mitochondria is the critical mediator involved in NRTI-induced inhibition of angiogenesis and lymphangiogenesis.
Discussion
The correlation between ART and cardiovascular disorders has only been partly explained (Jiang et al., 2007; Reyskens and Essop, 2014) ; however, the precise role of ART remains largely unknown. In the present study, the effect of NRTIs on vascular growth was first evaluated in primary cultures of human microvascular or microlymphatic ECs. Vascular ECs showed a normal survival status under NRTI treatment at the normal pharmacological dose. However, NRTIs suppressed vascular tube formation by arresting the proliferation and migration of ECs. This negative effect of NRTIs on neovascularization was further confirmed using in vivo models. VEGF-A, bFGF and VEGF-C, the typical vascular growth factors responsible for different stages of vascular growth, were administered to induce angiogenesis and lymphangiogenesis in the Matrigel plugs or ears of mice. The results showed that pretreatment with NRTIs markedly limited the formation of vascular networks. Furthermore, were obtained from five independent experiments. Data represent the means ± SEM of five independent experiments determined using densitometry relative to the corresponding total proteins in (A-I) and relative to GAPDH in (J-K). *P < 0.05 versus control; ns, not significant. mechanistic studies demonstrated that NRTIs dampened vascular growth factor-mediated angiogenic/lymphangiogenic signalling transduction in ECs. Therefore, the present study reveals that NRTIs have a direct inhibitory effect on endothelial angiogenesis and lymphangiogenesis. VEGF and FGF are critical factors in the regulation of angiogenesis and lymphangiogenesis, which function by activating corresponding RTK receptors on ECs (McColl et al., 2004; Yang et al., 2008; Lanahan et al., 2010; Eichmann and Simons, 2012) . VEGFR2 and FGFR are implicated in growth and haemostasis, respectively, in most aspects of normal and pathological vascular-endothelial-cell biology, whereas VEGFR3 is critical for lymphatic-endothelial-cell growth and function. In the present study, the NRTIs impaired the neovascularization induced by each growth factor (VEGF and bFGF) alone, indicating that NRTIs have an effect on RTK activation. Indeed, NRTIs suppressed RTK signal transduction both in vitro and in vivo. Therein, these results may reveal a molecular mechanism through which NRTIs retard angiogenesis. Furthermore, NRTIs had widespread effects on the functioning of RTKs. We observed that NRTIs not only inhibited VEGF-A/VEGFR2 and bFGF/FGFR1 signalling in ECs, but also attenuated VEGF-C-induced lymphangiogenesis and angiogenesis in vivo. However, the decreased neovessel formation in Matrigel/ear with VEGF-C cannot be attributed to the block of lymphangiogenesis. Recent studies indicate that VEGFR2 and VEGFR3 interact to induce angiogenesis; the two RTK signalling factors have different functions (Benedito et al., 2012; Zarkada et al., 2015) . Thus, NRTIs may affect the competitive interaction between VEGFR2 and VEGFR3 activation, leading to suppression of the VEGFR2 pathway in vascular angiogenesis.
Indeed, it is now well established that VEGFA/VEGFR2 is the primary signalling for angiogenesis, but its function typically requires the binding of VEGF-C and VEGFR2, while VEGFR3 functions as a trapper of VEGF-C, thus inhibiting VEGFR2 signalling (Hamada et al., 2000) . Therefore, TDF and other NRTI treatments may restrain VEGF-C-induced neovessel formation by enhancing the binding of VEGF-C to VEGFR3 in endothelial cells. On the other hand, the suppression by NRTIs of FGF-induced angiogenesis may be partly due to the blockage of the FGF signalling-maintained VEGFR2 expression (Murakami et al., 2011) and an effect on the docking protein FRS2α that would adapt the crosstalk between the two RTK pathways . Since the dose of NRTIs in the present study was similar to the serum concentration found in clinical treatments, these experimental phenotypes may reflect the development of endothelial dysfunction and impairments in angiogenesis/ lymphangiogenesis in patients receiving ART therapy.
The present study demonstrated that NRTI treatment suppresses the activation of the pathways through systematic effects on protein maturation, receptor phosphorylation and their downstream signal transduction pathways respectively. Notably, NRTIs affect VEGFR2, VEGFR3 and FGFR1, which are categorized as RTKs. However, NRTIs have little effect on the signalling of other endothelial membrane receptors, such as the NOTCH pathway. Thus, NRTIs negatively regulate EC growth by selectively dampening vascular growth factormediated RTK signalling. To further investigate this regulatory mechanism, the effects of NRTIs on RTK subcellular trafficking were investigated. Typically, RTKs are synthesized in the endoplasmic reticulum and subsequently transported onto the cell membrane via the Golgi apparatus NRTIs attenuate angiogenesis and lymphangiogenesis (Simons, 2012) . Constitutive internalization is part of the regular RTK cycling but is much slower than the return to the cell surface. Accordingly, RTK maintains abundant responsiveness to extracellular ligands (Eichmann and Simons, 2012; Simons, 2012; Zhang et al., 2013) . However, augmented endocytosis of endothelial RTKs is required for angiogenic signal transduction upon growth factor stimuli in vascular ECs (Eichmann and Simons, 2012) . The key events during this process are the clathrin-dependent internalization of ligand-occupied RTKs and their subsequent trafficking into EEA1-positive early endosomes, where downstream effectors of growth signalling are activated (Lanahan et al., 2010) . Meanwhile, ECs launch the resorting of RTK either for degradation or recycling back to cell membrane (Simons, 2012) . The present study demonstrated that NRTIs selectively block the entry of activated receptors into early endosomes, thereby disrupting angiogenic signalling in ECs. In contrast, the accumulation of RTKs on the cell membrane was not affected significantly by TDF and 3TC. Interestingly, AZT may define an important interfering step of NRTIs on RTK trafficking across the cell membrane. We observed that AZT induced an unique inhibitory effect on the maturation of the RTKs, partially decreasing their glycosylation. Glycosylation of these receptors is essential for protein maturation and their retention on the cell membrane for phosphorylation/activation (Takahashi and Shibuya, 1997; Shen et al., 1998; Markowska et al., 2011) . Therefore, AZT may disturb the surface expression and internalization of RTKs by evoking their deglycosylation. Details of this mechanism should be clarified in future studies. Mitochondrial toxicity is a common side effect of ART (Chattopadhyay and Aldous, 2016; Selvaraj et al., 2014) . With regard to the adverse cellular effects of NRTIs, we hypothesized that the mitochondria provide modulatory signals, which contribute to the behaviour of ECs. Low-levels of ROS derived from cytosolic NADPH oxidases have been reported to play a physiological role in the regulation of normal endothelial signalling. The cytosolic ROS directly oxidizes tyrosine phosphatases and consequently promotes the sustained activation of RTK signalling involved in angiogenesis (Hamanaka and Chandel, 2010) ; therefore, ROS generation in response to physiological environmental cues may support the normal or compensatory function of endothelial cells (Sena and Chandel, 2012) . In the present study, the MnSOD mimic MnTMPyP alleviated the NRTI-induced impairment of RTK signalling and angiogenic capability in ECs, suggesting that mitochondrial ROS may play a different role in angiogenesis. Compared with other cell types, the mitochondrial content in all ECs is low (2-6% of cytoplasm volume). Indeed, endothelial mitochondria are considered to be signal centres rather than energy producers; mitochondrial ROS is a pivotal mediator of endothelial cell behaviour (Freed and Gutterman, 2013; Tang et al., 2014) . In the present and previous studies, NRTI treatment resulted in mitochondrial dysfunction and the excessive production of mitochondrial ROS. The pathological accumulation of mitoROS may thereby mediate mitochondrial fission/fusion (Suen et al., 2008; Lugus et al., 2011; Shen et al., 2015) , mitophagy (Tang et al., 2014) , amino acid (Dang, 2012; DeBerardinis and Thompson, 2012; Kalhan and Hanson, 2012; Phang and Liu, 2012; Shyh-Chang et al., 2013) and fatty acid metabolization (Hulsmann and Dubelaar, 1988; Hulsmann and Dubelaar, 1992; Dagher et al., 1999; Dagher et al., 2001) , all well-known mitochondria-related events involved in RTK signalling and angiogenesis. Moreover, NRTIs may induce the overproduction of mitoROS, which then initiates a vicious cycle that exacerbates mitochondrial dysfunction and induces the further release of mitoROS, resulting in KDR signalling defects in endothelial cells. Therefore, NRTIinduced excessive mROS may act as a specific pathological signal in EC growth and angiogenesis.
In the present study, we identified the adverse effects of NRTIs, the most common class of ART in HIV infection, on vascular growth and development. In addition to the endothelial injury in arteriosclerosis, as the major concern of ART treatment, recent studies have also demonstrated other side effects of ART, such as endothelial cell senescence, renal endothelial dysfunction, endothelial activation and effects on endothelial progenitor cells (Zhan et al., 2016; Zungsontiporn et al., 2016; Echeverria et al., 2017; Meneses et al., 2017) . However, few studies have referred to the effect of ART on angiogenic capability of endothelial cells. To our knowledge, the present study is the first to systemically investigate the effect of ART on angiogenic characteristics of endothelial cells and vascular angiogenesis/lymphangiogenesis. These findings may apply to other ART drugs, such as protease inhibitors (PI) and integrase inhibitors, and suggest additional clinical strategies for preventing cardiovascular disease in AIDS patients with ART treatment. Moreover, the anti-angiogenesis effect of NRTIs can be explored to manipulate tumour angiogenesis, as indicated in the study of PI on KS (Sgadari et al., 2002) . The combination of NRTIs and PI could be developed as a novel 'cocktail' for the treatment of virus-related tumours.
Figure 5
NRTIs induce oxidative stress due to dysfunctional mitochondria in HMVECs and HDLECs. After TDF, AZT or 3TC treatment for 48 h, mitochondrial DNA copy number was assessed in HMVECs (A) and HDLECs (B). Data represent the means ± SEM of five independent experiments. *P < 0.05 versus control. (C-D) After TDF, AZT or 3TC treatment for 48 h, NRTI-induced an increase in mitochondrial ROS production, as determined using the mitochondria-targeted fluorescence probe mitoSOX. Representative images of HMVECs and HDLECs and corresponding quantitative analyses are shown in (C) and (D) for five independent experiments respectively. Scale bar represents 25 μm. (E, F) Cell lysates of control and NRTI-treated HMVECs and HDLECs were blotted with antibodies against MnSOD, catalase or Trx2. Representative images are shown in (E) and (F). Data in (E) and (F) represent the means ± SEM of five independent experiments relative to GAPDH determined using densitometry. *P < 0.05 versus control. ns, not significant.
Figure 6
MnTMPyP alleviates NRTI-induced angiogenic and lymphangiogenic defects in HMVECs and HDLECs. (A-D) Effects of MnTMPyP on tube formation in NRTI-treated HMVECs and HDLECs. HMVECs and HDLECs were treated with TDF, AZT or 3TC for 24 h and subsequently cultured without (control) or with MnTMPyP (2.5 μM) for 24 h. HMVECs or HDLECs were subsequently seeded in Matrigel for 6 h. Representative images are shown in (A) and (C). Branch points were quantified in (B) and (D). Data represent the means ± SEM from triplicates in each group from five independent experiments. Scale bar represents 100 μm. *P < 0.05. (E, F, H, I) Effects of MnTMPyP on VEGFR2 and FGFR1 signalling pathways in NRTI-treated HMVECs. HMVECs were treated with TDF or 3TC for 24 h and subsequently cultured without (control) or with MnTMPyP (2.5 μM) for 24 h. The activation of VEGFR2 and FGFR1 signalling pathways was determined as in Figure 3A , B. (G, J) Effects of MnTMPyP on VEGFR3 signalling pathway in NRTI-treated HDLECs. HDLECs were treated with TDF or 3TC for 24 h and subsequently cultured without (control) or with MnTMPyP (2.5 μM) for 24 h. The activation of VEGFR3 signalling pathway was determined as in Figure 3C . Representative images are shown in (E-J). Data in (E-J) represent mean ± SEM of five independent experiments relative to corresponding total proteins as determined by densitometry. *P < 0.05. control. (D) After TDF, AZT or 3TC treatment for 48 h, cell proliferation of HUVECs was measured using the Cell Counting Kit-8 assay. Data represent the means ± SEM from triplicates in each group from 5 independent experiments. *P < 0.05 vs. control. (E-F) After TDF, AZT or 3TC treatment for 48 h, HUVECs were subjected to transwell migration assay. Eight hours later, cells on the reverse side of the membrane were stained with crystal violet. Representative images are shown in E. Migratory cells were quantified in F. Data represent the means ± SEM from duplicates (6 different areas in each well) from 5 independent experiments. Scale bar, 100 μm. *P < 0.05 vs. control. (G-H) Tube formation assay in a Matrigel. After TDF, AZT or 3TC treatment for 48 h, HUVECs were seeded onto Matrigel for six hours and representative images are shown in G. Branch points were quantified in H. Data represent the means ± SEM from triplicates in each group from 5 independent experiments. Scale bar, 100 μm. *P < 0.05 vs. control. Figure S2 Microfilament organization was disrupted by NRTIs. Microfilaments of HMVECs, HUVECs and HDLECs were detected using Actin-Tracker Green. Representative images are shown in A-C, respectively. The data in A-C are based on 5 independent experiments. Scale bar, 25 μm. Figure S3 Matrigel mixed with either PBS (control), VEGF-A164 (50 ng·mL -1 ), bFGF (100 ng·mL -1 ) or VEGF-C (100 ng·mL -1 ) was placed subcutaneously in C57BL/6 mice previously fed with distilled water (control), AZT (100 mg·kg -1 ) or 3TC (100 mg·kg -1 ) for 5 days. On day 10, Matrigel plugs were harvested and recorded using stereomicroscopy. Representative images of plugs are shown in panels A, D, G, J, M and P, respectively. Matrigel plugs were subsequently sectioned, vascular and lymphatic vessels were subsequently assessed using immunofluorescence staining with anti-CD31 and anti-LYVE-I, respectively. Representative images of plugs with Ad-VEGF-A164, Ad-bFGF, and Ad-VEGF-C are shown in panels B, E, H, K, N and Q, respectively. Positive areas of new microvessels was quantified in C, F, I, L, O and R. Data represent the means ± SEM; n = 6 mice per group. Scale bar represents 50 μm. *P < 0.05 vs. control. Figure 
